Skip to main content
NOVOGENE CO., LTD. logo

NOVOGENE CO., LTD. — Investor Relations & Filings

Ticker · 688315 ISIN · CNE1000052X3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 558 across all filing types
Latest filing 2021-03-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688315

About NOVOGENE CO., LTD.

https://www.novogene.com

Novogene Co., Ltd. is a global provider of genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics analysis. The company offers a comprehensive suite of services, including whole genome sequencing, transcriptomics, epigenomics, and metagenomics, alongside specialized solutions for single-cell analysis and clinical diagnostics. Utilizing advanced high-throughput sequencing platforms and proprietary bioinformatics pipelines, Novogene supports research across diverse fields such as human health, agriculture, and environmental science. The organization serves a broad client base encompassing academic institutions, pharmaceutical companies, and biotechnology firms. With a focus on data quality and technical expertise, Novogene facilitates large-scale genomic studies and precision medicine initiatives through its network of high-capacity laboratories and integrated data management systems.

Recent filings

Filing Released Lang Actions
诺禾致源首次公开发行股票并在科创板上市招股意向书
Capital/Financing Update Classification · 95% confidence The document is titled as a 招股意向书 (Prospectus or Offering Intention Document) for the initial public offering (IPO) and listing on the Shanghai Stock Exchange STAR Market (科创板). It contains detailed information about the stock issuance, risk factors, financial data, company governance, business and technical details, and other disclosures typical of an IPO prospectus. The document is lengthy (15,000 characters) and includes substantive financial and operational information. This type of document is not an annual report, earnings release, or other routine financial report but is specifically related to the capital raising and listing process. According to the filing definitions, updates on company fundraising and capital structure changes fall under Capital/Financing Update (CAP). IPO prospectuses and related offering documents are best classified under CAP as they provide detailed information about the company's capital raising and issuance of new shares for listing. Therefore, the correct classification is Capital/Financing Update (CAP).
2021-03-22 Chinese
诺禾致源首次公开发行股票并在科创板上市招股意向书附录（一）
Regulatory Filings Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to the initial public offering (IPO) and listing of Beijing Novogene Technology Co., Ltd. on the STAR Market (科创板). It contains detailed information about the sponsor (underwriter), company background, legal and regulatory compliance, financial and operational risks, and the due diligence and internal review process conducted by the sponsor. The document is a formal underwriting and sponsorship report required for IPOs in China, which is distinct from an annual report, earnings release, or other financial filings. It is a comprehensive regulatory filing related to the IPO process, but it is not a financial report like a 10-K or interim report. It is also not a simple announcement or certification but a substantive document supporting the IPO application. Given the nature of the document as a sponsorship letter for an IPO, it best fits under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory documents that do not fit other categories such as M&A, capital updates, or earnings releases.
2021-03-22 Chinese
诺禾致源首次公开发行股票并在科创板上市招股意向书附录（二）
Annual Report Classification · 95% confidence The document contains detailed financial data for multiple years, including net profit, earnings per share, and other financial metrics. It also includes an audit report section with references to an unqualified audit opinion by an accounting firm (立信), and a comprehensive legal opinion letter from a law firm regarding the company's initial public offering (IPO) and listing on the Science and Technology Innovation Board (科创板). The document discusses the company's compliance with various laws and regulations, corporate governance, shareholder meetings, board resolutions, and other legal and financial prerequisites for the IPO. The length of the document (15,000 characters) and the depth of financial and legal information indicate this is a full official yearly report covering company activity and full financial performance, consistent with an Annual Report (10-K equivalent). It is not merely an announcement or a certification, but contains substantive financial data and legal opinions supporting the IPO. Therefore, the document is best classified as an Annual Report (10-K). FY 2020
2021-03-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.